Routine versus clinical failure participant demographics, ART history, & clinical characteristics.

† Time on therapy collected on study CRFs but only available for patients enrolled under routine monitoring eligibility. ART time was abstracted from clinic records for all enrolled participants.° Symptoms included: Herpes Zoster, popular pruritic eruption, unexplained chronic diarrhea (>1 month), unexplained persistent fever, moderate unexplained weight loss, oral candidiasis, esophageal candidiasis, pulmonary TB, extra-pulmonary TB, pneumonia, Crytpococcal meningitis, Kaposi’s Sarcoma, and Other.‡ Reported values based on per protocol assessment (plasma or vDBS if available). Median and IQR unchanged among suppressed group if using fsDBS only. Median [IQR] based on fsDBS among patients with elevated VL per fsDBS results was 30,870 [17,156–121,306].3TC—Lamivudine; ART—antiretroviral therapy; AZT—Zidovudine; CRF—case report form; d4T —Stavudine; DBS—dried blood spot; EFV—Efavirenz; IQR—interquartile range; NVP—Nevirapine; SD—standard deviation; TB—tuberculosis; TDF—Tenofovir; VL—viral load.Routine versus clinical failure participant demographics, ART history, & clinical characteristics.